Modified GRF 1-29 (also known as Mod GRF or CJC-1295 without DAC) is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of the native peptide with modifications to increase stability and half-life. It acts on GHRH receptors in the pituitary gland to stimulate the release of endogenous growth hormone, and is studied for its potential in hormone regulation, growth promotion, and metabolic effects. The modified structure provides improved resistance to enzymatic degradation compared to natural GHRH while maintaining similar receptor binding and activation properties.

Overview

Modified GRF 1-29 (also known as Mod GRF 1-29, tetrasubstituted GRF 1-29, or by its research designation CJC-1295 without DAC) is a synthetic peptide analog of the biologically active N-terminal 29-amino-acid fragment of human growth hormone-releasing hormone (GHRH). The native GHRH(1-29) sequence (sermorelin) retains full receptor-binding activity but is rapidly degraded in vivo by dipeptidyl peptidase IV (DPP-IV), which cleaves the Tyr1-Ala2 bond, yielding a plasma half-life of only 5–7 minutes. Modified GRF 1-29 addresses this limitation through four strategic amino acid substitutions — typically at positions 2 (D-Ala), 8 (Gln→Ala), 15 (Gly→Ala), and 27 (Met→Leu) — which confer resistance to DPP-IV cleavage and improve chemical stability, extending the effective half-life to approximately 30 minutes while maintaining full agonist activity at the GHRH receptor.

The mechanism of action of Modified GRF 1-29 involves binding to GHRH receptors on anterior pituitary somatotroph cells, activating the Gs-adenylyl cyclase-cAMP-PKA signaling cascade that triggers growth hormone (GH) synthesis and secretion. Importantly, this stimulation preserves the body's natural pulsatile GH release pattern and negative feedback regulation through IGF-1 and somatostatin, avoiding the supraphysiological, continuous GH elevation associated with exogenous recombinant GH administration. Clinical studies with GHRH analogs have demonstrated significant increases in GH pulse amplitude, circulating IGF-1 levels, lean body mass, and reductions in visceral adiposity. The related compound tesamorelin (Egrifta), which is also a modified GRF analog, received FDA approval in 2010 for the reduction of excess abdominal fat in HIV-associated lipodystrophy.

Modified GRF 1-29 is most commonly used in combination with growth hormone-releasing peptides (GHRPs) — ghrelin mimetics such as Ipamorelin, GHRP-2, or GHRP-6 — because GHRH and ghrelin act through complementary receptors to produce synergistic GH release far exceeding either stimulus alone. The standard research protocol involves subcutaneous injection of 100 mcg Modified GRF 1-29 combined with 100–200 mcg of a GHRP, administered 1–3 times daily (typically at bedtime to coincide with natural GH pulses, and optionally post-exercise and upon waking). This combination approach has become the foundation of peptide-based GH optimization protocols, preferred over direct GH administration for its physiological release pattern and lower risk profile. Side effects are generally mild and may include injection site reactions, facial flushing, headache, and transient water retention. Modified GRF 1-29 is distinct from CJC-1295 with DAC, which adds a Drug Affinity Complex to bind albumin and extend the half-life to 6–8 days, producing more continuous (rather than pulsatile) GH elevation.

Mechanism of Action

Structural Modifications

Modified GRF 1-29 retains the biologically active N-terminal 29 residues of native GHRH(1-44) with four strategic amino acid substitutions: Ala2 → D-Ala2 (DPP-IV resistance), Asn8 → Gln8 (asparagine rearrangement prevention), Ala15 → Ala15 (or Leu15), and Met27 → Leu27 or Nle27 (oxidation resistance). These modifications extend the effective half-life from approximately 5-7 minutes (native GHRH) to approximately 30 minutes while preserving full GHRHR binding affinity and efficacy.

GHRH Receptor Signaling Cascade

Modified GRF 1-29 binds the GHRH receptor (GHRHR), a class B G protein-coupled receptor expressed predominantly on anterior pituitary somatotrophs. Receptor activation couples to Gsα, stimulating adenylyl cyclase and elevating intracellular cAMP. cAMP activates protein kinase A (PKA), which phosphorylates CREB (cAMP response element-binding protein) at Ser133, driving transcription of the GH1 gene and Pit-1 expression. PKA also directly facilitates exocytosis of GH-containing secretory granules.

Pulsatile GH Release Pattern

Unlike continuous GH elevation (which downregulates GH receptor sensitivity), Modified GRF 1-29 preserves the physiological pulsatile GH secretion pattern. Administered during the trough between natural GH pulses or timed with endogenous GHRH release, it amplifies pulse amplitude without altering pulse frequency. This pulsatile pattern is critical for maintaining hepatic GH receptor sensitivity and optimal IGF-1 production via the JAK2/STAT5b pathway.

Synergy with GH Secretagogues

Modified GRF 1-29 produces synergistic GH release when combined with ghrelin mimetics (GHRP-6, GHRP-2, Ipamorelin, hexarelin). The GHRHR (cAMP/PKA) and GHS-R1a (PLC/PKC/Ca²⁺) pathways converge on somatotroph calcium mobilization and vesicle exocytosis, producing GH release that is 5-10 fold greater than either pathway alone. This mirrors the physiological synergy between hypothalamic GHRH and ghrelin.

Feedback Regulation

GH and IGF-1 produced in response to Modified GRF 1-29 activate negative feedback at multiple levels: hypothalamic somatostatin release is increased, GHRH neuron activity is suppressed, and pituitary GHS-R1a expression is modulated. This built-in feedback prevents excessive GH elevation and maintains physiological regulation, distinguishing Modified GRF 1-29 from exogenous GH administration which bypasses these controls.

Reconstitution Calculator

Research

Safety Profile

Side effects are typically mild and transient, including injection site flushing, warmth, and dizziness. It should be used with caution in individuals with active cancer or diabetic retinopathy. Long-term safety is not fully established, and it should be avoided during pregnancy and breastfeeding.

Pharmacokinetic Profile